Medtronic plc - MDT STOCK NEWS

Medtronic plc (NYSE: MDT) announced a cash dividend of $0.58 per ordinary share for Q4 FY 2021, a 7.4% increase from the previous year, reflecting its commitment to returning value to shareholders. This dividend is payable on April 16, 2021, to shareholders on record by March 26, 2021. Medtronic continues to be a part of the S&P 500 Dividend Aristocrats index, having increased its annual dividends for 43 consecutive years. The announcement aligns with prior communications made in May 2020.

Medtronic plc (NYSE: MDT) has commenced its pivotal trial for the PulseSelect™ Pulsed Field Ablation (PFA) System, aimed at treating atrial fibrillation (AF). The trial, known as PULSED AF, is the first global study with investigational device exemption approval, assessing safety and efficacy across up to 500 patients in the U.S., Canada, Europe, and Australia. PulseSelect employs a non-thermal approach to disrupt irregular heart rhythms, potentially reducing damage to surrounding tissues. Preliminary results from pilot studies showed promising efficacy with no procedural complications.

Medtronic plc (NYSE:MDT) has released new findings from the REVERSE trial, demonstrating the long-term benefits of cardiac resynchronization therapy (CRT) for patients with mild heart failure. The study indicates that patients who stabilize with CRT have similar longevity to those who improve, with five-year mortality rates at 10% for improved/stabilized patients versus 21% for worsened cases. The trial involved 406 patients, revealing a 73% lower risk of dying for CRT patients who stabilized compared to those whose condition worsened. The results emphasize the need for redefining CRT response classifications.

Medtronic plc (NYSE:MDT) reported Q3 fiscal 2021 results, showing revenue of $7.775 billion, a 0.8% increase as reported but a 1.0% decline organically. GAAP diluted EPS was $0.94, while non-GAAP diluted EPS fell 10% to $1.29. U.S. revenue decreased 2%, while non-U.S. developed markets increased 6% as reported. The Cardiac and Vascular Group saw a 4.0% decrease in revenue, and the Minimally Invasive Therapies Group experienced a 6.3% increase, partly due to COVID-19 related products. The firm refrained from providing formal financial guidance due to ongoing uncertainties.

Medtronic (NYSE:MDT) announced FDA approval for expanded MRI labeling of its InterStim™ II and InterStim™ Micro sacral neuromodulation systems using SureScan™ MRI leads. This updated labeling enhances MRI scan parameters and reduces wait times, improving patient access. New features include increased B1+rms settings for MRI scans and reduced maximum duration scan wait times from 60 to 5 minutes. The SureScan technology eliminates impedance checks before MRI, streamlining patient care. Medtronic continues to innovate in SNM therapy, highlighting over 70 FDA approvals for its InterStim portfolio.

Medtronic plc (NYSE: MDT) announced its participation in several upcoming virtual investor conferences. Key details include:

• SVB Leerink Global Healthcare Conference on February 24, 2021, at 9:20 AM EST, featuring Mike Weinstein.
• Citi's Healthcare Services Conference on February 25, 2021, at 2:25 PM EST, with Brett Wall speaking.
• Cowen Annual Healthcare Conference on March 2, 2021, at 12:50 PM EST, featuring Karen Parkhill.
• Oppenheimer Healthcare Conference on March 16, 2021, at 1:10 PM EDT, with Sean Salmon.

Webcasts will be available on Medtronic's investor relations page.

On February 17, 2021, Medtronic plc (NYSE:MDT) announced a global recall of its Valiant Navion thoracic stent graft system due to safety concerns. This decision followed reports of stent fractures and associated serious complications in patients from the Valiant Evo Global Clinical Trial. Notably, one patient death was reported, and seven out of 87 patients showed stent ring enlargement. Medtronic is conducting a thorough investigation and has urged physicians to cease use of the device while prioritizing patient safety.

Medtronic plc (NYSE:MDT) will report its third quarter financial results for fiscal year 2021 on February 23, 2021, at 5:45 a.m. CST. The report will include financial data for the quarter ending January 29, 2021. Medtronic will hold a video webcast to discuss these results at 7:00 a.m. CST, available on their investor relations website. Future earnings releases are also scheduled through fiscal year 2022.

Medtronic (NYSE:MDT) announced that leading spine surgeons in the U.S. have successfully performed surgeries using its Mazor Robotic Guidance System with newly cleared navigated disc prep and Midas Rex™ drills. These minimally invasive procedures demonstrate improved precision and planning, enhancing patient outcomes. Surgeons report significant benefits, including faster recoveries and reduced pain for patients. The technology's versatility allows seamless integration into existing workflows, even amidst the challenges posed by the COVID-19 pandemic.